FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 67 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR New on NCI’s Websites for March 2021 March 25, 2021 FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial... July 23, 2021 FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... July 24, 2024 Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following... April 2, 2024 Load more HOT NEWS ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy Brain Cancer Cells Hijack Gene “On Switches” to Drive Tumor Growth Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in... Community Comes Together To Give Terminally Ill Father One Last Christmas...
